Landmark Agreement: Pfizer Cuts U.S. Drug Prices Up to 85% After Pact with Trump Administration

Pfizer has signed a confidential agreement with the Trump Administration aimed at significantly lowering the cost of prescription medicines for U.S. patients while reinforcing America’s global leadership in biopharmaceutical innovation. As part of this pact, Pfizer will offer substantial price reductions, particularly through a new direct purchasing platform.

Key Terms of the Agreement (Voluntarily Implemented by Pfizer)

Lower U.S. Prices: Pfizer has agreed to implement measures to ensure that Americans receive drug prices comparable to those available in other developed countries.
Pricing Parity: Newly launched medicines will be priced at parity with other key developed markets.
Direct Purchasing Platform: Pfizer will participate in a direct purchasing platform, TrumpRx.gov, allowing U.S. patients to buy medicines at a significant discount.

Price Reductions

The price cuts, applied to the majority of the Company’s primary care treatments and select specialty brands purchased directly, are as follows:

Savings Range: Up to 85% and an average of 50%.
Specific Examples (Direct Purchase Discounts):
- Eucrisa (atopic dermatitis ointment): 80% discount.
- Xeljanz (rheumatoid arthritis, psoriatic arthritis, ulcerative colitis): 40% discount.
- Zavzpret (migraines): 50% discount.

Industry & Economic Impact

End of Global Burden: Pfizer CEO Albert Bourla stated that the agreement ends the days when American families “alone carried the global burden of paying for innovation,” ensuring prices in the U.S. and other developed countries are reasonable and sustainable.
Investment Commitment: The agreement provides “certainty and stability” on pricing and tariffs, leading to a massive increase in U.S. investment:
- New Investment: An additional $70 billion dedicated to U.S. research, development, and capital projects in the next few years.
- Total Commitment: This builds upon Pfizer’s previous $83 billion investment in American biotech innovation from 2018–2024.
Tariff Grace Period: Pfizer has secured a three-year grace period during which its products under a Section 232 investigation will not face tariffs, provided the company further invests in U.S. manufacturing.
Strategic Focus: With the agreement in place, Pfizer plans to sharpen its R&D focus on areas like oncology, obesity, vaccines, and inflammation and immunology.

Context from the Trump Administration

President Trump highlighted the significant price disparity, noting that the prices Americans pay for brand-name drugs are often more than three times the price paid by other developed nations. He emphasized that roughly 75% of global pharmaceutical profits come from American taxpayers, effectively subsidizing lower prices abroad.